This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
April 26, 2012 4:30 pm ET
Peter C. Farrell - Founder, Executive Chairman, Chief Executive Officer and President
Brett A. Sandercock - Chief Financial Officer and Principal Accounting Officer
Unknown Executive -
Michael J. Farrell - President of Americas Operations
Geoff Neilson - President of Respiratory Care Strategic Business Unit
Robert Douglas - Chief Operating Officer
David Low - Deutsche Bank AG, Research Division
Ben Andrew - William Blair & Company L.L.C., Research Division
Matthew Prior - BofA Merrill Lynch, Research Division
Joanne K. Wuensch - BMO Capital Markets U.S.
David C. Clair - Piper Jaffray Companies, Research Division
Saul Hadassin - Crédit Suisse AG, Research Division
David Stanton - Nomura Securities Co. Ltd., Research Division
Steven D. Wheen - JP Morgan Chase & Co, Research Division
Ben C. Haynor - Feltl and Company, Inc., Research Division
Michael Matson - Mizuho Securities USA Inc., Research Division
Good day, ladies and gentlemen, and welcome to the Third Quarter 2012 ResMed Incorporated Earnings Conference Call. My name is Angela, and I will be your coordinator for today. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.
The company has asked me to read -- address certain matters. First, ResMed does not authorize the recording of any portion of this conference call for any purpose. Second, during the conference call, ResMed may make forward-looking statements such as: Projections of future revenue or earnings, new product development or new markets for the company's products. These statements are made under the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Risks and uncertainties exist that could cause actual results to materially differ from the forward-looking statements.